Table 1.

Patient demographics and clinical characteristics at start of EV therapy.

	Overall Cohort (N= 29)	Responders (N=12)	Non-Responders (N=17)
Median age (years)	70	74	69
Gender – n (%)
Male	24 (83%)	10 (83%)	14 (82%)
Female	5 (17%)	2 (17%)	3 (18%)
Race/Ethnicity– n (%)
Asian	8 (28%)	2 (17%)	6 (35%)
Black or African American	2 (7%)	0 (0%)	2 (12%)
Hispanic or Latino	1 (3%)	1 (8%)	0 (0%)
White	18 (62%)	9 (75%)	9 (53%)
Primary tumor location – n (%)
Bladder	22 (76%)	9 (75%)	13 (76%)
Upper Tract	5 (17%)	2 (17%)	3 (18%)
Urethra	2 (7%)	1 (8%)	1 (6%)
Histology – n (%)
Pure Urothelial	13 (45%)	7 (58%)	6 (35%)
Variant Component	14 (48%)	5 (42%)	9 (53%)
Pure Variant	2 (7%)	0 (0%)	2 (12%)
Smoking history (present or former) – n (%)	20 (69%)	8 (67%)	12 (71%)
Median BMI (kg/m²)	23.97	24.08	24.43
Visceral metastases – n (%)	21 (72%)	8 (67%)	13 (76%)
Bone metastases – n (%)	12 (41%)	4 (33%)	8 (47%)
Liver metastases – n (%)	9 (31%)	3 (25%)	6 (35%)
ECOG – n (%)
0 or 1	19 (66%)	9 (75%)	10 (59%)
≥ 2	9 (31%)	2 (17%)	7 (41%)
Unknown	1 (3%)	1 (8%)	0 (0%)
Hemoglobin – n (%)
< 10 g/dL	6 (21%)	2 (17%)	4 (24%)
≥ 10 d/dL	20 (69%)	9 (75%)	11 (65%)
Unknown	3 (10%)	1 (8%)	2 (12%)
Albumin – n (%)
< 3 g/dL	6 (21%)	2 (17%)	4 (24%)
≥ 3 g/dL	20 (69%)	9 (75%)	11 (65%)
Unknown	3 (10%)	1 (8%)	2 (12%)
eGFR – n (%)
< 60 mL/min/1.73m2	17 (59%)	8 (67%)	9 (53%)
≥ 60 mL/min/1.73m2	9 (31%)	3 (25%)	6 (35%)
Unknown	3 (10%)	1 (8%)	2 (12%)
NLR – n (%)
< 5	17 (59%)	5 (42%)	12 (71%)
≥ 5	9 (31%)	6 (50%)	3 (18%)
Unknown	3 (10%)	1 (8%)	2 (12%)